Baiji Shenzhou PD-1 inhibitor price dropped by 80%
It is reported that the new price of PD-1 monoclonal antibody baizean (tirilizumab injection), which was independently developed by Baiji Shenzhou, was as low as 2180 yuan / piece (100mg) before medical insurance reimbursement, with a price drop of as much as 80%. The annual treatment cost was less than 75000 yuan, and the annual treatment burden of patients with medical insurance reimbursement indications was lower. This time, bazaar was included in the medical insurance for two indications, including for the treatment of recurrent or refractory classical Hodgkin's lymphoma (R / R CHL) and locally advanced or metastatic urothelial carcinoma (UC). Bazaar has become the only PD-1 monoclonal antibody with the medical insurance reimbursement qualification for urothelial carcinoma indications.
This text is a result of machine translation.
Related companies：
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Feb 05, 2021 02:07 PM
· Healthcare
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
In depth
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Healthcare, Real Estate, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Industrials, Financials, Consumer StaplesLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 20, 2020 02:22 PM
· Healthcare
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Briefing Dec 16, 2020 02:27 PM
· Healthcare
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Briefing Nov 20, 2020 08:14 PM
· Healthcare
Pfizer submitted to FDA for authorization of emergency use of new crown vaccine
Briefing Nov 19, 2020 09:33 AM
· Healthcare
Baiji Shenzhou: midterm analysis of the global phase III clinical trial for the treatment of non-small cell lung cancer reached the main end point
Briefing Jul 14, 2020 11:02 AM
· Healthcare
Hillhouse Will Inject USD 1 billion in BeiGene's Share Sale
See more
Read next
In depth
Technology
Huawei 'Strikes Back': Global 5G Patent Battle Might Be Getting Started
Apr 18, 2021 10:53 PM
Financials · Analysis
Digital Currency Electronic Payment: Not A Warning Sign for Alipay and WeChat Pay
Apr 16, 2021 10:07 AM
Insight
Technology, Communication
Three Opportunities Brought by Archegos Capital's Outburst
Apr 12, 2021 12:31 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.